Xencor, Inc.

About Xencor, Inc.

Xencor is a biotechnology company focused on expanding the therapeutic boundaries of antibody drugs. Using its proprietary XmAb protein engineering platform, Xencor develops a broad pipeline of drug candidates optimized to treat cancer and other serious diseases, with over 20 programs in clinical testing and many in preclinical development. Three XmAb medicines are marketed through partnerships.

Products & Services

XmAb819 (ENPP3 x CD3):A drug candidate in the pipeline targeting specific cancer therapies.

XmAb541 (CLDN6 x CD3):A pipeline product focused on cancer therapy.

Plamotamab (CD20 x CD3):A drug candidate for cancer treatment in development.

XmAb942 (Xtend TL1A):A therapeutic candidate with extended half-life technology.

XmAb657 (CD19 x CD3):A pipeline drug targeting specific immune responses for cancer.

Bispecific Fc Domains:Technology enabling antibodies to address multiple disease targets.

Cytotoxic Fc Domains:Technology for enhancing antibody cytotoxicity in therapies.

Immune Inhibitor Fc Domains:Technology for modulating immune responses in treatments.

Specialties

Antibody Therapeutics Bispecific Antibodies Fc Domain Engineering Cancer Immunotherapy Immune Modulation

Funding History

Debug: View Raw Funding Data

#	Type	Amount Fields	Date Fields	Investors
1	RT: Public Offering T: - FT: Public Offering	A: 201300000 MR: - FA: approximately $201.3 million FAN: 201300000	D: 2024-09-12 FD: 2024-09-12	4 investors
2	RT: Public Offering T: - FT: Public Offering	A: 175000000 MR: - FA: $175 million FAN: 175000000	D: 2024-09-11 FD: 2024-09-11	4 investors

Public Offering Latest

2024-09-12

$201.3M

4 investors (Pro only)

Public Offering 2024-09-11

$175.0M

View 1 more funding rounds with Pro

Unlock Full Funding History

Growth Metrics

+45%

Employee Growth

YoY

3.2x

Funding Growth

Last Round

12

Markets

Operating

10K+

Customers

Active

View 3 more growth metrics with Pro

Unlock All Metrics

Mock Up

Team & Leadership

B

Bassil I. Dahiyat

President & Chief Executive Officer, Director

J

John R. Desjarlais

Executive Vice President, Research & Chief Scientific Officer

C

Celia Eckert

Senior Vice President, General Counsel & Corporate Secretary

B

Bart Cornelissen

Senior Vice President & Chief Financial Officer

R

Raymond Deshaies

Director

E

Ellen G. Feigal

Director

View 16 more team members with Pro

Unlock Full Team Directory

Recent News

Xencor, Inc. Announces New Product Launch

2 days ago

Company unveils innovative solution to transform the industry, expanding market reach and capabilities...

Leadership Team Expands with Industry Veteran

1 week ago

New executive brings 20+ years of experience to accelerate growth and strategic initiatives...

Company Recognized as Industry Leader

2 weeks ago

Receives prestigious award for innovation and customer satisfaction in competitive market...

Key Competitors

C1

Competitor Alpha

Series B · $50M raised

C2

Competitor Beta

Series C · $120M raised

C3

Competitor Gamma

Series A · $25M raised

C4

Competitor Delta

Seed · $10M raised